Annexon: ARCHER-II Readout and GBS Approval - H.C. Wainwright Raises Price Target to 25 USD!
Reading Time: 3 minutes
H.C. Wainwright considers the stock of Annexon (ANNX) (i.) to be significantly undervalued and raises the price target to 25 USD, primarily supported by approval progress. The business model is based on the targeted blockade of the C1q molecule to treat neuroinflammatory diseases at their biological origin. With upcoming ARCHER-II data and the GBS approval application, the company is operationally transitioning to the commercial phase. Inhibition of the C1q molecule as a therapeutic basis Annexon operates as a biopharmaceutical company...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
